Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders

Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders

Abstract Demyelinating disorders are among the most common and debilitating diseases in neurology. Canavan disease (CD) is a lethal demyelinating disease caused by mutation of the aspartoacylase (ASPA) gene, which leads to the accumulation of its substrate N‐acetyl‐l‐aspartate (NAA), and consequentl...

Full description

Bibliographic Details
Main Authors: Lizhao Feng, Jianfei Chao, Peng Ye, Qui Luong, Guoqiang Sun, Wei Liu, Qi Cui, Sergio Flores, Natasha Jackson, Afm Nazmul Hoque Shayento, Guihua Sun, Zhenqing Liu, Weidong Hu, Yanhong Shi
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Advanced Science
Subjects:
allogeneic cell therapy
Canavan disease
demyelinating diseases
iPSCs
off‐the‐shelf cell therapy
oligodendrocyte progenitor cells (OPC)
Online Access:https://doi.org/10.1002/advs.202206910

Internet

https://doi.org/10.1002/advs.202206910

Similar Items